Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22932338 | 0.83 | CNR1 (0.32) | RARBCNR1HDAC1HDAC8HDAC6 | |
| SCHEMBL24755068 | 0.83 | CACNA1H (0.32) | TRPM8HDAC1HDAC8HDAC6CACNA1B | |
| SCHEMBL22931785 | 0.79 | ABL1 (0.33) | RARBCNR1HDAC1HDAC8HDAC6 | |
| SCHEMBL22931772 | 0.77 | LIPE (0.37) | LIPEMT-CO2CACNA1GCACNA1BCACNA1C | |
| SCHEMBL29806156 | 0.77 | LIPE (0.37) | LIPEMT-CO2CACNA1GCACNA1BCACNA1C | |
| SCHEMBL22931767 | 0.74 | EPHX2 (0.37) | — | |
| SCHEMBL29806705 | 0.73 | LIPE (0.35) | LIPEMT-CO2HDAC1HDAC6ABCG2 | |
| SCHEMBL24755009 | 0.73 | LIPE (0.35) | LIPEMT-CO2HDAC1HDAC6ABCG2 | |
| SCHEMBL22932193 | 0.72 | EPHX2 (0.37) | — | |
| SCHEMBL29420795 | 0.72 | EPHX2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402900-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | BASILEA PHARM INT AG (CH) | 2022-12-22 | — | — | US | disclosed |
| WO-2021018869-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | Basilea Pharmaceutica International AG (CH) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402900-A1 | 1,2,4-OXADIAZOL-5-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | OXER1, CBR3, CCNY | LIPE 4733/4885RARB 696/4885TRPM8 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.